Previous 10 | Next 10 |
IDEAYA Announces Presentations at AACR Annual Meeting 2021 for Synthetic Lethality Programs IDE397 and PARG, and Kinase Inhibitor IDE196 PR Newswire SOUTH SAN FRANCISCO, Calif. , March 11, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synth...
IDEAYA to Participate in Upcoming March 2021 Investor Relations Events PR Newswire SOUTH SAN FRANCISCO, Calif. , March 1, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to ...
IDEAYA Biosciences Announces Inaugural Synthetic Lethality Investor Day ‒ IDEAYA's inaugural Synthetic Lethality Investor Day is planned for April 20, 2021 with scientific presentations from IDEAYA and GSK scientific leaders, and several Key Opinion Leaders ‒ T...
IDEAYA Biosciences Appoints Susan L. Kelley, M.D., an Industry Veteran in Medical Oncology and Clinical Development, to its Board of Directors - Dr. Susan L. Kelley was a former clinical development executive in oncology with Bayer and Bristol Myers Squibb, and led the developme...
Ideaya Biosciences (IDYA) announces the effectiveness of Investigational New Drug ((IND)) application for a Phase 1 clinical trial to evaluate IDE397, a methionine adenosyltransferase 2a (MAT2A) inhibitor.IDE397 is being developed for cancer patients harboring methylthioadenosine phospho...
IDEAYA Announces IDE397 IND Clearance by U.S. FDA to Initiate Phase 1 and Appointment of Matthew Maurer, M.D., as Vice President, Head of Clinical Oncology and Medical Affairs ‒ Targeting First-Patient-In for IDE397 Phase 1 study in Q1 2021, as a potential best-in-class M...
IDEAYA to Participate in Upcoming February 2021 Investor Relations Events PR Newswire SOUTH SAN FRANCISCO, Calif. , Feb. 1, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and...
Ideaya Biosciences ([[IDYA]] +0.8%) sold ~3.1M shares for aggregate gross proceeds of ~50M at a weighted average price of $16.08 per share.Jefferies, the sales agent, receives 3% commission of the aggregate gross proceeds.Press Release For further details see: Ideaya Biosciences sells ~...
Spelman College and IDEAYA Biosciences Announce Partnership for Professional Development of the Next Generation of Female African American Leaders in the Biotechnology Industry PR Newswire ATLANTA , Ga. and SOUTH SAN FRANCISCO, Calif. , Jan. 19, 2021 /PR...
IDEAYA Biosciences (IDYA) has submitted an Investigational New Drug ((IND)) application with the FDA for the initiation of a Phase 1 clinical trial to evaluate IDE397 for the treatment of patients having solid tumors with methylthioadenosine phosphorylase ((MTAP)) deletion.IDEAYA Bioscie...
News, Short Squeeze, Breakout and More Instantly...
IDEAYA Biosciences Inc. Company Name:
IDYA Stock Symbol:
NASDAQ Market:
IDEAYA Biosciences Inc. Website:
IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event PR Newswire SOUTH SAN FRANCISCO, Calif. , July 29, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery an...
2024-07-10 16:15:02 ET RBC Capital analyst issues OUTPERFORM recommendation for IDYA on July 10, 2024 02:51PM ET. The previous analyst recommendation was Outperform. IDYA was trading at $37.33 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-07-10 16:00:03 ET Gregory Renza from RBC Capital issued a price target of $61.00 for IDYA on 2024-07-10 14:51:00. The adjusted price target was set to $61.00. At the time of the announcement, IDYA was trading at $37.33. The overall price target consensus is at $35.3...